| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Placenta | 16 | 2024 | 58 | 7.320 |
Why?
|
| Pregnancy Trimester, First | 15 | 2024 | 18 | 6.300 |
Why?
|
| Polycystic Ovary Syndrome | 15 | 2026 | 20 | 5.580 |
Why?
|
| Reproductive Techniques, Assisted | 14 | 2023 | 15 | 5.370 |
Why?
|
| Pregnancy | 46 | 2026 | 599 | 4.510 |
Why?
|
| Infertility, Female | 13 | 2021 | 18 | 4.470 |
Why?
|
| Infertility | 9 | 2023 | 11 | 4.040 |
Why?
|
| Female | 87 | 2026 | 4060 | 4.010 |
Why?
|
| Sex Characteristics | 7 | 2024 | 39 | 3.800 |
Why?
|
| Humans | 84 | 2026 | 6794 | 3.080 |
Why?
|
| Placentation | 7 | 2019 | 12 | 3.070 |
Why?
|
| Fertilization in Vitro | 15 | 2023 | 19 | 2.760 |
Why?
|
| Granulosa Cells | 11 | 2019 | 12 | 2.610 |
Why?
|
| DNA Methylation | 5 | 2024 | 26 | 2.480 |
Why?
|
| Forkhead Transcription Factors | 9 | 2012 | 10 | 2.350 |
Why?
|
| Adult | 38 | 2026 | 2113 | 2.330 |
Why?
|
| Transcriptome | 7 | 2024 | 31 | 2.260 |
Why?
|
| Pregnancy Outcome | 11 | 2024 | 42 | 2.000 |
Why?
|
| MicroRNAs | 3 | 2022 | 54 | 1.800 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2024 | 23 | 1.720 |
Why?
|
| Insulin Resistance | 5 | 2024 | 74 | 1.710 |
Why?
|
| Pregnancy Complications | 6 | 2024 | 44 | 1.680 |
Why?
|
| Fertility | 6 | 2019 | 8 | 1.550 |
Why?
|
| Hyperandrogenism | 6 | 2024 | 6 | 1.550 |
Why?
|
| Chorionic Villi | 3 | 2025 | 3 | 1.290 |
Why?
|
| Pregnancy Trimester, Third | 3 | 2024 | 7 | 1.250 |
Why?
|
| Fetal Development | 5 | 2022 | 28 | 1.170 |
Why?
|
| Fertilization | 5 | 2023 | 5 | 1.160 |
Why?
|
| Male | 19 | 2024 | 3671 | 1.140 |
Why?
|
| RNA, Messenger | 7 | 2024 | 190 | 1.120 |
Why?
|
| Cesarean Section | 3 | 2018 | 18 | 1.110 |
Why?
|
| Trophoblasts | 5 | 2025 | 8 | 1.110 |
Why?
|
| Reproductive Health | 2 | 2017 | 9 | 1.050 |
Why?
|
| Maternal Age | 2 | 2018 | 5 | 1.000 |
Why?
|
| Retrospective Studies | 13 | 2026 | 681 | 0.990 |
Why?
|
| Gene Expression Regulation | 5 | 2021 | 120 | 0.990 |
Why?
|
| Gestational Age | 5 | 2022 | 58 | 0.990 |
Why?
|
| Genome-Wide Association Study | 2 | 2023 | 8 | 0.970 |
Why?
|
| Chorionic Villi Sampling | 6 | 2025 | 6 | 0.970 |
Why?
|
| Pregnancy, Ectopic | 4 | 2017 | 6 | 0.960 |
Why?
|
| Metabolic Syndrome | 1 | 2026 | 35 | 0.950 |
Why?
|
| Gene Expression Profiling | 3 | 2021 | 44 | 0.950 |
Why?
|
| Infant, Newborn | 8 | 2024 | 199 | 0.920 |
Why?
|
| Primary Ovarian Insufficiency | 3 | 2011 | 4 | 0.890 |
Why?
|
| Endometriosis | 2 | 2023 | 6 | 0.800 |
Why?
|
| Treatment Outcome | 8 | 2020 | 500 | 0.740 |
Why?
|
| Estradiol | 9 | 2026 | 57 | 0.700 |
Why?
|
| Hypothalamic Diseases | 3 | 2026 | 3 | 0.690 |
Why?
|
| Cell Differentiation | 3 | 2025 | 101 | 0.690 |
Why?
|
| Risk Factors | 10 | 2022 | 767 | 0.680 |
Why?
|
| Infertility, Male | 2 | 2017 | 6 | 0.680 |
Why?
|
| Receptor Cross-Talk | 1 | 2020 | 5 | 0.670 |
Why?
|
| Live Birth | 5 | 2022 | 6 | 0.670 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2020 | 20 | 0.670 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2019 | 93 | 0.660 |
Why?
|
| Repressor Proteins | 2 | 2011 | 13 | 0.660 |
Why?
|
| Ovary | 6 | 2024 | 19 | 0.660 |
Why?
|
| Pre-Eclampsia | 2 | 2017 | 12 | 0.640 |
Why?
|
| Cohort Studies | 8 | 2024 | 285 | 0.630 |
Why?
|
| Young Adult | 12 | 2026 | 567 | 0.620 |
Why?
|
| Menstrual Cycle | 2 | 2021 | 11 | 0.620 |
Why?
|
| Animals | 18 | 2026 | 1875 | 0.620 |
Why?
|
| Phosphoproteins | 3 | 2012 | 9 | 0.610 |
Why?
|
| Pluripotent Stem Cells | 1 | 2019 | 6 | 0.610 |
Why?
|
| Androgens | 4 | 2023 | 24 | 0.610 |
Why?
|
| Embryo Transfer | 3 | 2021 | 5 | 0.600 |
Why?
|
| Amenorrhea | 5 | 2026 | 5 | 0.590 |
Why?
|
| Forkhead Box Protein L2 | 8 | 2012 | 8 | 0.570 |
Why?
|
| Cardiovascular Diseases | 2 | 2023 | 172 | 0.570 |
Why?
|
| Delivery, Obstetric | 1 | 2018 | 16 | 0.550 |
Why?
|
| Case-Control Studies | 7 | 2021 | 108 | 0.550 |
Why?
|
| Signal Transduction | 4 | 2026 | 246 | 0.550 |
Why?
|
| Transcription Factors | 3 | 2008 | 53 | 0.540 |
Why?
|
| Length of Stay | 2 | 2017 | 53 | 0.540 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2017 | 2 | 0.530 |
Why?
|
| Infant, Premature, Diseases | 1 | 2017 | 7 | 0.530 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2017 | 7 | 0.520 |
Why?
|
| Embryo Loss | 1 | 2017 | 1 | 0.520 |
Why?
|
| Cryopreservation | 1 | 2017 | 2 | 0.520 |
Why?
|
| Middle Aged | 10 | 2026 | 2108 | 0.520 |
Why?
|
| Transcription, Genetic | 4 | 2010 | 40 | 0.520 |
Why?
|
| Cross-Sectional Studies | 11 | 2026 | 506 | 0.510 |
Why?
|
| Up-Regulation | 1 | 2017 | 94 | 0.510 |
Why?
|
| GATA3 Transcription Factor | 1 | 2016 | 1 | 0.510 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2016 | 7 | 0.510 |
Why?
|
| Aromatase | 3 | 2012 | 8 | 0.490 |
Why?
|
| Placenta Diseases | 1 | 2015 | 1 | 0.480 |
Why?
|
| United States | 6 | 2023 | 1019 | 0.470 |
Why?
|
| Follicle Stimulating Hormone | 4 | 2026 | 15 | 0.460 |
Why?
|
| Metabolic Diseases | 1 | 2015 | 13 | 0.460 |
Why?
|
| Genetic Counseling | 1 | 2015 | 8 | 0.450 |
Why?
|
| Prenatal Diagnosis | 1 | 2015 | 11 | 0.450 |
Why?
|
| Basal Metabolism | 1 | 2015 | 2 | 0.450 |
Why?
|
| Testosterone | 5 | 2023 | 50 | 0.450 |
Why?
|
| Referral and Consultation | 1 | 2015 | 61 | 0.440 |
Why?
|
| Placenta, Retained | 1 | 2014 | 2 | 0.440 |
Why?
|
| Oocytes | 3 | 2011 | 9 | 0.440 |
Why?
|
| Mutation | 3 | 2024 | 97 | 0.430 |
Why?
|
| Epigenesis, Genetic | 3 | 2022 | 36 | 0.420 |
Why?
|
| Prevalence | 4 | 2017 | 259 | 0.410 |
Why?
|
| Cholesterol Side-Chain Cleavage Enzyme | 2 | 2012 | 2 | 0.410 |
Why?
|
| Cyclin D2 | 2 | 2012 | 2 | 0.410 |
Why?
|
| Progesterone | 4 | 2019 | 14 | 0.400 |
Why?
|
| RNA | 3 | 2022 | 25 | 0.400 |
Why?
|
| Sequence Analysis, RNA | 2 | 2024 | 3 | 0.380 |
Why?
|
| Biomarkers | 6 | 2026 | 214 | 0.370 |
Why?
|
| Down-Regulation | 1 | 2012 | 57 | 0.370 |
Why?
|
| Body Mass Index | 4 | 2026 | 145 | 0.370 |
Why?
|
| Hirsutism | 2 | 2023 | 4 | 0.360 |
Why?
|
| Child | 3 | 2024 | 524 | 0.360 |
Why?
|
| Phenotype | 4 | 2024 | 91 | 0.360 |
Why?
|
| Gene Expression | 3 | 2022 | 77 | 0.350 |
Why?
|
| Protein Multimerization | 1 | 2011 | 3 | 0.350 |
Why?
|
| Smad Proteins | 1 | 2011 | 10 | 0.350 |
Why?
|
| Prospective Studies | 6 | 2024 | 331 | 0.350 |
Why?
|
| Mice | 7 | 2026 | 746 | 0.340 |
Why?
|
| Menstruation Disturbances | 2 | 2021 | 2 | 0.340 |
Why?
|
| Chromosome Aberrations | 1 | 2010 | 4 | 0.330 |
Why?
|
| Inflammation | 2 | 2026 | 143 | 0.320 |
Why?
|
| DNA | 4 | 2017 | 39 | 0.310 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2009 | 1 | 0.310 |
Why?
|
| Promoter Regions, Genetic | 4 | 2012 | 45 | 0.310 |
Why?
|
| Small Ubiquitin-Related Modifier Proteins | 1 | 2009 | 3 | 0.310 |
Why?
|
| Embryo Implantation | 3 | 2021 | 8 | 0.310 |
Why?
|
| Infant | 3 | 2024 | 187 | 0.310 |
Why?
|
| Ultrasonography, Prenatal | 4 | 2015 | 21 | 0.300 |
Why?
|
| Spermatozoa | 3 | 2023 | 9 | 0.290 |
Why?
|
| Maternal Health | 2 | 2019 | 4 | 0.280 |
Why?
|
| Mosaicism | 1 | 2008 | 1 | 0.280 |
Why?
|
| Severity of Illness Index | 3 | 2021 | 118 | 0.280 |
Why?
|
| Infant, Premature | 2 | 2018 | 23 | 0.270 |
Why?
|
| DNA-Binding Proteins | 2 | 2005 | 38 | 0.270 |
Why?
|
| Cricetulus | 4 | 2012 | 6 | 0.270 |
Why?
|
| CHO Cells | 4 | 2012 | 7 | 0.270 |
Why?
|
| Cricetinae | 4 | 2012 | 11 | 0.270 |
Why?
|
| Adolescent | 5 | 2026 | 869 | 0.270 |
Why?
|
| Diet | 2 | 2026 | 111 | 0.270 |
Why?
|
| Health Status | 2 | 2017 | 83 | 0.250 |
Why?
|
| Micronutrients | 1 | 2026 | 4 | 0.240 |
Why?
|
| Butyrophilins | 1 | 2026 | 1 | 0.240 |
Why?
|
| Leukocyte Common Antigens | 1 | 2026 | 1 | 0.240 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2026 | 12 | 0.240 |
Why?
|
| Energy Intake | 1 | 2026 | 30 | 0.240 |
Why?
|
| Age Distribution | 2 | 2017 | 45 | 0.240 |
Why?
|
| Autoimmune Diseases | 1 | 2026 | 9 | 0.240 |
Why?
|
| Glomerulonephritis | 1 | 2026 | 4 | 0.240 |
Why?
|
| Endothelium, Vascular | 1 | 2026 | 30 | 0.240 |
Why?
|
| Cytokines | 1 | 2026 | 80 | 0.230 |
Why?
|
| Stem Cells | 1 | 2025 | 19 | 0.230 |
Why?
|
| Mental Health | 1 | 2026 | 70 | 0.230 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2024 | 2 | 0.220 |
Why?
|
| Hydrocephalus | 1 | 2024 | 2 | 0.220 |
Why?
|
| RNA, Small Interfering | 2 | 2016 | 26 | 0.220 |
Why?
|
| Reproduction | 1 | 2004 | 4 | 0.220 |
Why?
|
| Ultrasonography | 1 | 2024 | 38 | 0.220 |
Why?
|
| Attitude of Health Personnel | 1 | 2004 | 36 | 0.210 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2024 | 19 | 0.210 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2023 | 6 | 0.210 |
Why?
|
| Physicians | 1 | 2004 | 49 | 0.210 |
Why?
|
| Semen | 1 | 2023 | 3 | 0.210 |
Why?
|
| Pregnancy Rate | 3 | 2021 | 5 | 0.200 |
Why?
|
| Social Media | 1 | 2024 | 13 | 0.200 |
Why?
|
| Gene Frequency | 1 | 2003 | 12 | 0.200 |
Why?
|
| Alleles | 1 | 2003 | 22 | 0.200 |
Why?
|
| Dietary Supplements | 1 | 2024 | 44 | 0.200 |
Why?
|
| Receptors, Progesterone | 1 | 2003 | 11 | 0.200 |
Why?
|
| PPAR gamma | 1 | 2023 | 51 | 0.200 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2019 | 34 | 0.200 |
Why?
|
| Brachytherapy | 1 | 2003 | 1 | 0.200 |
Why?
|
| Urinary Incontinence, Stress | 1 | 2003 | 8 | 0.190 |
Why?
|
| Hysterectomy | 1 | 2003 | 12 | 0.190 |
Why?
|
| Delirium | 1 | 2022 | 4 | 0.190 |
Why?
|
| Urinary Tract Infections | 1 | 2022 | 9 | 0.190 |
Why?
|
| Amniocentesis | 2 | 2015 | 3 | 0.190 |
Why?
|
| Folic Acid Antagonists | 2 | 1999 | 3 | 0.180 |
Why?
|
| Methotrexate | 2 | 1999 | 11 | 0.180 |
Why?
|
| Cell Line | 2 | 2025 | 124 | 0.180 |
Why?
|
| Pregnancy, Abdominal | 2 | 1999 | 2 | 0.180 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2003 | 92 | 0.180 |
Why?
|
| Health Status Disparities | 1 | 2023 | 83 | 0.180 |
Why?
|
| Intrauterine Devices, Medicated | 1 | 2021 | 1 | 0.180 |
Why?
|
| Levonorgestrel | 1 | 2021 | 2 | 0.180 |
Why?
|
| Uterine Diseases | 1 | 2021 | 3 | 0.180 |
Why?
|
| Chlamydia Infections | 1 | 2021 | 8 | 0.180 |
Why?
|
| Maternal Serum Screening Tests | 1 | 2021 | 1 | 0.180 |
Why?
|
| Child, Preschool | 2 | 2024 | 258 | 0.180 |
Why?
|
| Placenta Accreta | 1 | 2021 | 2 | 0.180 |
Why?
|
| Obesity | 1 | 2024 | 226 | 0.170 |
Why?
|
| Computational Biology | 1 | 2021 | 13 | 0.170 |
Why?
|
| Logistic Models | 3 | 2016 | 165 | 0.170 |
Why?
|
| Reproducibility of Results | 2 | 2021 | 112 | 0.170 |
Why?
|
| Nerve Tissue Proteins | 2 | 2016 | 25 | 0.170 |
Why?
|
| Decidua | 1 | 2020 | 2 | 0.170 |
Why?
|
| Mice, Inbred C57BL | 4 | 2026 | 258 | 0.170 |
Why?
|
| Endometrium | 1 | 2021 | 24 | 0.170 |
Why?
|
| Self-Assessment | 1 | 2020 | 5 | 0.170 |
Why?
|
| Comparative Genomic Hybridization | 2 | 2017 | 3 | 0.160 |
Why?
|
| California | 2 | 2020 | 230 | 0.160 |
Why?
|
| Reproductive Medicine | 1 | 2020 | 1 | 0.160 |
Why?
|
| Academic Success | 1 | 2020 | 3 | 0.160 |
Why?
|
| Endocrinologists | 1 | 2020 | 10 | 0.160 |
Why?
|
| Publications | 1 | 2020 | 5 | 0.160 |
Why?
|
| Ovulation | 3 | 2021 | 5 | 0.160 |
Why?
|
| Endocrinology | 1 | 2020 | 19 | 0.160 |
Why?
|
| Biomedical Research | 1 | 2020 | 34 | 0.160 |
Why?
|
| Genomic Imprinting | 1 | 2019 | 2 | 0.150 |
Why?
|
| Observational Studies as Topic | 1 | 2019 | 9 | 0.150 |
Why?
|
| Risk Assessment | 2 | 2020 | 197 | 0.150 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 104 | 0.150 |
Why?
|
| Metabolomics | 1 | 2019 | 4 | 0.150 |
Why?
|
| Child Health | 1 | 2019 | 8 | 0.150 |
Why?
|
| Animals, Outbred Strains | 2 | 2012 | 2 | 0.150 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 82 | 0.150 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2022 | 279 | 0.140 |
Why?
|
| Birth Weight | 1 | 2018 | 33 | 0.140 |
Why?
|
| Cells, Cultured | 4 | 2012 | 234 | 0.130 |
Why?
|
| Health Status Indicators | 1 | 2017 | 10 | 0.130 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2017 | 14 | 0.130 |
Why?
|
| Organ Size | 1 | 2017 | 31 | 0.130 |
Why?
|
| Premature Birth | 1 | 2017 | 8 | 0.130 |
Why?
|
| Child Development | 1 | 2017 | 21 | 0.130 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 98 | 0.130 |
Why?
|
| Blood Glucose | 3 | 2024 | 188 | 0.130 |
Why?
|
| Pilot Projects | 1 | 2017 | 89 | 0.130 |
Why?
|
| Prenatal Education | 1 | 2016 | 1 | 0.130 |
Why?
|
| GTP-Binding Proteins | 1 | 2016 | 1 | 0.130 |
Why?
|
| Apc2 Subunit, Anaphase-Promoting Complex-Cyclosome | 1 | 2016 | 1 | 0.130 |
Why?
|
| Natural Childbirth | 1 | 2016 | 2 | 0.130 |
Why?
|
| Genetic Loci | 1 | 2016 | 2 | 0.130 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2016 | 2 | 0.130 |
Why?
|
| Chemokines, CXC | 1 | 2016 | 4 | 0.130 |
Why?
|
| Prenatal Care | 1 | 2016 | 13 | 0.130 |
Why?
|
| Cell Culture Techniques | 1 | 2016 | 18 | 0.130 |
Why?
|
| Cell Movement | 1 | 2016 | 38 | 0.130 |
Why?
|
| Prognosis | 1 | 2017 | 220 | 0.120 |
Why?
|
| Incidence | 1 | 2017 | 197 | 0.120 |
Why?
|
| Medical Records | 1 | 2016 | 23 | 0.120 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 23 | 0.120 |
Why?
|
| Membrane Glycoproteins | 1 | 2016 | 65 | 0.120 |
Why?
|
| Causality | 1 | 2015 | 8 | 0.120 |
Why?
|
| Colorectal Neoplasms | 1 | 2016 | 23 | 0.120 |
Why?
|
| Ovulation Induction | 3 | 2020 | 5 | 0.120 |
Why?
|
| Sarcopenia | 1 | 2016 | 19 | 0.120 |
Why?
|
| Endometritis | 1 | 2015 | 6 | 0.120 |
Why?
|
| Fetal Growth Retardation | 1 | 2015 | 42 | 0.110 |
Why?
|
| Fetus | 1 | 2015 | 125 | 0.110 |
Why?
|
| Electric Impedance | 1 | 2015 | 6 | 0.110 |
Why?
|
| Prolactin | 1 | 2015 | 23 | 0.110 |
Why?
|
| Blastomeres | 1 | 2014 | 1 | 0.110 |
Why?
|
| Cleavage Stage, Ovum | 1 | 2014 | 1 | 0.110 |
Why?
|
| Immunohistochemistry | 2 | 2017 | 118 | 0.110 |
Why?
|
| Aneuploidy | 1 | 2014 | 3 | 0.110 |
Why?
|
| Preimplantation Diagnosis | 1 | 2014 | 2 | 0.110 |
Why?
|
| Oocyte Retrieval | 2 | 2012 | 2 | 0.110 |
Why?
|
| Thyrotropin | 1 | 2015 | 51 | 0.110 |
Why?
|
| Anti-Mullerian Hormone | 1 | 2014 | 1 | 0.110 |
Why?
|
| Ovarian Reserve | 1 | 2014 | 1 | 0.110 |
Why?
|
| Genes, BRCA1 | 1 | 2014 | 2 | 0.110 |
Why?
|
| Germ-Line Mutation | 1 | 2014 | 28 | 0.110 |
Why?
|
| Recombinant Proteins | 2 | 2012 | 45 | 0.110 |
Why?
|
| Rats | 6 | 2005 | 571 | 0.100 |
Why?
|
| Insulin | 3 | 2024 | 146 | 0.100 |
Why?
|
| Los Angeles | 1 | 2014 | 321 | 0.100 |
Why?
|
| Laparoscopy | 3 | 2016 | 21 | 0.100 |
Why?
|
| Two-Hybrid System Techniques | 2 | 2010 | 2 | 0.100 |
Why?
|
| Gene Silencing | 1 | 2012 | 6 | 0.090 |
Why?
|
| Receptors, Adiponectin | 1 | 2012 | 1 | 0.090 |
Why?
|
| Cumulus Cells | 1 | 2012 | 1 | 0.090 |
Why?
|
| Embryonic Development | 1 | 2012 | 2 | 0.090 |
Why?
|
| Adiponectin | 1 | 2012 | 6 | 0.090 |
Why?
|
| Transfection | 2 | 2010 | 56 | 0.090 |
Why?
|
| Phosphorylation | 2 | 2010 | 73 | 0.090 |
Why?
|
| Chronic Disease | 2 | 2026 | 167 | 0.090 |
Why?
|
| Molecular Sequence Data | 2 | 2009 | 70 | 0.090 |
Why?
|
| Mutant Proteins | 1 | 2011 | 2 | 0.090 |
Why?
|
| Binding Sites | 1 | 2011 | 24 | 0.090 |
Why?
|
| Smad2 Protein | 1 | 2011 | 2 | 0.090 |
Why?
|
| Smad3 Protein | 1 | 2011 | 2 | 0.090 |
Why?
|
| Smad4 Protein | 1 | 2011 | 3 | 0.090 |
Why?
|
| Diagnosis, Differential | 2 | 2021 | 79 | 0.090 |
Why?
|
| Surveys and Questionnaires | 2 | 2020 | 280 | 0.090 |
Why?
|
| Ovarian Follicle | 1 | 2011 | 2 | 0.090 |
Why?
|
| Chromosome Disorders | 1 | 2010 | 2 | 0.080 |
Why?
|
| Risk | 1 | 2010 | 43 | 0.080 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2010 | 9 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 90 | 0.080 |
Why?
|
| Sequence Alignment | 1 | 2009 | 6 | 0.080 |
Why?
|
| Amino Acid Sequence | 1 | 2009 | 38 | 0.080 |
Why?
|
| Cell Nucleus | 1 | 2009 | 38 | 0.080 |
Why?
|
| Luteinization | 1 | 2008 | 1 | 0.070 |
Why?
|
| Forkhead Box Protein O1 | 1 | 2008 | 2 | 0.070 |
Why?
|
| Forkhead Box Protein O3 | 1 | 2008 | 3 | 0.070 |
Why?
|
| Sex Chromosome Aberrations | 1 | 2008 | 2 | 0.070 |
Why?
|
| Karyotyping | 1 | 2008 | 5 | 0.070 |
Why?
|
| Cell Cycle Proteins | 1 | 2008 | 22 | 0.070 |
Why?
|
| Diet Records | 1 | 2026 | 6 | 0.060 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2026 | 5 | 0.060 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2026 | 5 | 0.060 |
Why?
|
| Th17 Cells | 1 | 2026 | 4 | 0.060 |
Why?
|
| C-Reactive Protein | 1 | 2026 | 36 | 0.060 |
Why?
|
| RNA Helicases | 1 | 2005 | 3 | 0.060 |
Why?
|
| Double-Blind Method | 1 | 2026 | 101 | 0.060 |
Why?
|
| Hormones | 2 | 2022 | 11 | 0.060 |
Why?
|
| Biopsy | 1 | 2025 | 36 | 0.060 |
Why?
|
| Mice, Knockout | 1 | 2026 | 150 | 0.060 |
Why?
|
| Nutritional Status | 1 | 2026 | 64 | 0.060 |
Why?
|
| Relaxin | 1 | 2005 | 1 | 0.060 |
Why?
|
| Dietary Proteins | 1 | 2026 | 53 | 0.060 |
Why?
|
| Genomics | 1 | 2005 | 13 | 0.060 |
Why?
|
| Research | 1 | 2005 | 26 | 0.060 |
Why?
|
| Tripartite Motif Proteins | 1 | 2024 | 3 | 0.060 |
Why?
|
| Peptide Hormones | 1 | 2004 | 5 | 0.060 |
Why?
|
| Glycoproteins | 1 | 2004 | 10 | 0.060 |
Why?
|
| Paracrine Communication | 1 | 2004 | 9 | 0.050 |
Why?
|
| Zebrafish | 1 | 2004 | 5 | 0.050 |
Why?
|
| Proline-Rich Protein Domains | 1 | 2004 | 2 | 0.050 |
Why?
|
| Protein Structure, Tertiary | 1 | 2004 | 3 | 0.050 |
Why?
|
| Mutagenesis | 1 | 2004 | 8 | 0.050 |
Why?
|
| Cell Survival | 1 | 2004 | 33 | 0.050 |
Why?
|
| Alanine | 1 | 2004 | 4 | 0.050 |
Why?
|
| Societies, Medical | 1 | 2004 | 67 | 0.050 |
Why?
|
| Apoptosis | 1 | 2005 | 179 | 0.050 |
Why?
|
| Peptides | 1 | 2004 | 19 | 0.050 |
Why?
|
| Consumer Health Information | 1 | 2024 | 3 | 0.050 |
Why?
|
| Information Dissemination | 1 | 2024 | 16 | 0.050 |
Why?
|
| Glucose Tolerance Test | 1 | 2024 | 40 | 0.050 |
Why?
|
| Testis | 1 | 2023 | 6 | 0.050 |
Why?
|
| Gene Knockout Techniques | 1 | 2023 | 4 | 0.050 |
Why?
|
| Oxidative Phosphorylation | 1 | 2023 | 3 | 0.050 |
Why?
|
| Adenosine Triphosphate | 1 | 2023 | 17 | 0.050 |
Why?
|
| Mitochondrial Proteins | 1 | 2023 | 15 | 0.050 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2023 | 12 | 0.050 |
Why?
|
| Patient Education as Topic | 1 | 2024 | 58 | 0.050 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2003 | 8 | 0.050 |
Why?
|
| Receptors, Corticotropin-Releasing Hormone | 1 | 2003 | 7 | 0.050 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 2003 | 21 | 0.050 |
Why?
|
| Epithelium | 1 | 2023 | 22 | 0.050 |
Why?
|
| Urodynamics | 1 | 2003 | 4 | 0.050 |
Why?
|
| Hypothalamus | 1 | 2003 | 49 | 0.050 |
Why?
|
| Radiation Dosage | 1 | 2003 | 8 | 0.050 |
Why?
|
| Combined Modality Therapy | 1 | 2003 | 33 | 0.050 |
Why?
|
| Escherichia coli | 1 | 2022 | 8 | 0.050 |
Why?
|
| Neoplasm Staging | 1 | 2003 | 45 | 0.050 |
Why?
|
| Endothelial Cells | 1 | 2023 | 17 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2022 | 45 | 0.050 |
Why?
|
| Epithelial Cells | 1 | 2023 | 49 | 0.050 |
Why?
|
| Estrogens | 1 | 2022 | 27 | 0.050 |
Why?
|
| Oligomenorrhea | 1 | 2022 | 2 | 0.050 |
Why?
|
| Disease Models, Animal | 1 | 2022 | 231 | 0.040 |
Why?
|
| Tissue Adhesions | 1 | 2021 | 4 | 0.040 |
Why?
|
| Placenta Previa | 1 | 2021 | 1 | 0.040 |
Why?
|
| Nanostructures | 1 | 2021 | 1 | 0.040 |
Why?
|
| Cell Aggregation | 1 | 2021 | 3 | 0.040 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2021 | 2 | 0.040 |
Why?
|
| ROC Curve | 1 | 2021 | 28 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2004 | 282 | 0.040 |
Why?
|
| Neoplasm Proteins | 1 | 2001 | 18 | 0.040 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2021 | 1 | 0.040 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2021 | 5 | 0.040 |
Why?
|
| Quality of Life | 1 | 2003 | 184 | 0.040 |
Why?
|
| Telephone | 1 | 2020 | 4 | 0.040 |
Why?
|
| Dehydroepiandrosterone | 1 | 2000 | 6 | 0.040 |
Why?
|
| Self Report | 1 | 2020 | 35 | 0.040 |
Why?
|
| Efficiency | 1 | 2020 | 1 | 0.040 |
Why?
|
| Specialty Boards | 1 | 2020 | 1 | 0.040 |
Why?
|
| Peer Review, Research | 1 | 2020 | 2 | 0.040 |
Why?
|
| Certification | 1 | 2020 | 4 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 127 | 0.040 |
Why?
|
| Publishing | 1 | 2020 | 11 | 0.040 |
Why?
|
| Time Factors | 1 | 2021 | 321 | 0.040 |
Why?
|
| Cyclic AMP | 3 | 2004 | 30 | 0.040 |
Why?
|
| Receptors, Estrogen | 1 | 1999 | 32 | 0.040 |
Why?
|
| Microinjections | 1 | 1999 | 3 | 0.040 |
Why?
|
| Embryo, Mammalian | 1 | 1999 | 15 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 268 | 0.040 |
Why?
|
| Odds Ratio | 1 | 1999 | 82 | 0.040 |
Why?
|
| Life Style | 1 | 1999 | 51 | 0.040 |
Why?
|
| Salpingostomy | 1 | 1998 | 1 | 0.040 |
Why?
|
| Chorionic Gonadotropin, beta Subunit, Human | 1 | 1998 | 1 | 0.040 |
Why?
|
| Trisomy | 1 | 2017 | 2 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2017 | 50 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2016 | 6 | 0.030 |
Why?
|
| Choice Behavior | 1 | 2016 | 11 | 0.030 |
Why?
|
| Elective Surgical Procedures | 1 | 2016 | 5 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2016 | 109 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2014 | 5 | 0.030 |
Why?
|
| Blastocyst | 1 | 2014 | 5 | 0.030 |
Why?
|
| Cell Count | 1 | 2014 | 18 | 0.030 |
Why?
|
| Receptors, Peptide | 2 | 2005 | 2 | 0.030 |
Why?
|
| Genes, BRCA2 | 1 | 2014 | 4 | 0.030 |
Why?
|
| BRCA2 Protein | 1 | 2014 | 12 | 0.030 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2005 | 18 | 0.030 |
Why?
|
| BRCA1 Protein | 1 | 2014 | 13 | 0.030 |
Why?
|
| Mesencephalon | 1 | 1994 | 1 | 0.030 |
Why?
|
| Septum Pellucidum | 1 | 1994 | 2 | 0.030 |
Why?
|
| Abnormalities, Multiple | 1 | 1994 | 6 | 0.030 |
Why?
|
| Hypopituitarism | 1 | 1994 | 4 | 0.030 |
Why?
|
| Chorionic Gonadotropin | 2 | 2004 | 4 | 0.020 |
Why?
|
| Aged | 1 | 2016 | 1539 | 0.020 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2005 | 1 | 0.010 |
Why?
|
| DEAD Box Protein 20 | 1 | 2005 | 1 | 0.010 |
Why?
|
| Gonads | 1 | 2005 | 1 | 0.010 |
Why?
|
| Gonadotropins, Equine | 1 | 2004 | 1 | 0.010 |
Why?
|
| Theca Cells | 1 | 2004 | 2 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2004 | 8 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2004 | 10 | 0.010 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2004 | 14 | 0.010 |
Why?
|
| Luteinizing Hormone | 1 | 2004 | 19 | 0.010 |
Why?
|
| Protein Binding | 1 | 2004 | 29 | 0.010 |
Why?
|
| Proteins | 1 | 2004 | 41 | 0.010 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2003 | 1 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2003 | 9 | 0.010 |
Why?
|
| Vasopressins | 1 | 2003 | 9 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2003 | 18 | 0.010 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2003 | 13 | 0.010 |
Why?
|
| Pro-Opiomelanocortin | 1 | 2003 | 21 | 0.010 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2003 | 25 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2003 | 110 | 0.010 |
Why?
|
| Dexamethasone | 1 | 2003 | 30 | 0.010 |
Why?
|
| Fatty Acid-Binding Protein 7 | 1 | 2001 | 1 | 0.010 |
Why?
|
| Gonadotropins | 1 | 2001 | 2 | 0.010 |
Why?
|
| Receptors, Interleukin-4 | 1 | 2001 | 2 | 0.010 |
Why?
|
| DNA Probes | 1 | 2001 | 5 | 0.010 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2001 | 3 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2001 | 13 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2001 | 25 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2001 | 29 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2001 | 28 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2000 | 155 | 0.010 |
Why?
|
| Colforsin | 1 | 1999 | 7 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 1999 | 9 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1999 | 24 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 1999 | 12 | 0.010 |
Why?
|
| Puberty, Delayed | 1 | 1994 | 2 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 1994 | 64 | 0.010 |
Why?
|